Literature DB >> 8890397

Uric acid stones.

J R Asplin1.   

Abstract

Uric acid is the end product of purine degradation in humans. It is a weak acid with a pK of 5.35 in urine. In acidic urine the undissociated form of uric acid predominates and is poorly soluble, leading to crystalluria and stone formation. Uric acid stones account for 5% to 10% of all stones in the United States. Acidic urine, hyperuricosuria, and low urine volume are the risk factors for uric acid stone formation. Uric acid stones may be idiopathic or secondary to a systemic disease such as gout. Treatment includes alkalinization of the urine, high fluid intake, and reduction of uric acid excretion if it is abnormal.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890397

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  22 in total

1.  Effect of two sports drinks on urinary lithogenicity.

Authors:  Jeffrey W Goodman; John R Asplin; David S Goldfarb
Journal:  Urol Res       Date:  2008-12-10

2.  Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi.

Authors:  Osama El-Gamal; Mohamed El-Bendary; Maged Ragab; Mohamed Rasheed
Journal:  Urol Res       Date:  2011-08-21

3.  Identification of a new candidate locus for uric acid nephrolithiasis.

Authors:  M N Ombra; P Forabosco; S Casula; A Angius; G Maestrale; E Petretto; G Casu; G Colussi; E Usai; P Melis; M Pirastu
Journal:  Am J Hum Genet       Date:  2001-04-17       Impact factor: 11.025

Review 4.  The crystallization of monosodium urate.

Authors:  Miguel A Martillo; Lama Nazzal; Daria B Crittenden
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

Review 5.  Update on the pathophysiology and management of uric acid renal stones.

Authors:  Jon-Emile S Kenny; David S Goldfarb
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

6.  Dietary treatment of nephrolithiasis.

Authors:  Antonio Nouvenne; Tiziana Meschi; Angela Guerra; Franca Allegri; Beatrice Prati; Loris Borghi
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

Review 7.  Recent advances in the pathophysiology of nephrolithiasis.

Authors:  Khashayar Sakhaee
Journal:  Kidney Int       Date:  2008-12-10       Impact factor: 10.612

8.  Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Authors:  F Perez-Ruiz; A Alonso-Ruiz; M Calabozo; A Herrero-Beites; G García-Erauskin; E Ruiz-Lucea
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

9.  Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.

Authors:  Haibo Yu; Xinying Liu; Yaxiang Song; Jiafen Cheng; Hui Bao; Ling Qin; Xuan Zhou; Ling Wang; Ai Peng
Journal:  Clin Exp Nephrol       Date:  2018-05-14       Impact factor: 2.801

Review 10.  Epidemiology and clinical pathophysiology of uric acid kidney stones.

Authors:  Khashayar Sakhaee
Journal:  J Nephrol       Date:  2014-02-05       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.